Clinical Trial Update: A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors [Phase 1]

View source ↗

Summary

Phase I trial comparing HLX17 to Keytruda in multiple solid tumors to evaluate pharmacokinetics, preliminary efficacy, safety, and immunogenicity; recruitment i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• HLX17
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Non-small Cell Lung Cancer, Melanoma | Phase 1 | Status: RECRUITING